Insulin tumours of the pancreas
| Autor: | P. R. Daggett, L.P. Le Quesne |
|---|---|
| Rok vydání: | 1983 |
| Předmět: |
endocrine system
medicine.medical_specialty education.field_of_study geography geography.geographical_feature_category endocrine system diseases business.industry Insulin medicine.medical_treatment Population Islet medicine.disease medicine.anatomical_structure Endocrinology Internal medicine Laparotomy medicine Diazoxide education Pancreas business Insulinoma Contraindication medicine.drug |
| DOI: | 10.1016/b978-0-407-02317-8.50012-4 |
| Popis: | Publisher Summary This chapter discusses the pathology, diagnosis, and management of insulin secreting islet cell tumor of the pancreas— insulinoma. Insulin tumors of the pancreas emphasizes that the diagnosis of insulinoma or hypersecretion of insulin can be made with great accuracy today. The chapter also explains the glucose/insulin ratio to be critical in establishing the diagnosis. Although pro-insulin is assayed routinely, rather than C-peptide, each is equally valuable in addition to the measurement of insulin and glucose. The insulinoma occurs with an annual incidence of 0.5 to 1.25 per million of the population and is slightly commoner in women than in men. Once the diagnosis of insulinoma is made, it is important to avoid further episodes of hypoglycaemia. This can be achieved by giving frequent high-carbohydrate snacks or with the drug diazoxide. This thiazide powerfully inhibits the release of insulin from the pancreatic islet β-cell and is effective in preventing episodes of hypoglycaemia when there is an insulinoma. It may be used for long-term treatment when there is a contraindication to operation or when the tumor cannot be found at laparotomy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|